Elysia Alvarez1, Sheri L Spunt2, Marcio Malogolowkin1, Qian Li3, Ted Wun3, Ann Brunson3, Steven Thorpe, Sara Kreimer2, Theresa Keegan3. 1. Division of Pediatric Hematology/Oncology, University of California Davis School of Medicine, Sacramento, California, USA. 2. Division of Pediatric Hematology/Oncology, Stanford University School of Medicine, Stanford, California, USA. 3. Division of Hematology/Oncology, Center for Oncology, Hematology Outcomes Research and Training (COHORT), University of California Davis School of Medicine, Sacramento, California, USA.
Abstract
Background: Soft tissue sarcomas (STS) are a heterogeneous group of tumors whose management benefits from a multidisciplinary therapeutic approach. Published data suggest that cancer treatment at a specialized cancer center (SCC) can improve survival in other cancers. Therefore, we examined the impact of the location of treatment on survival in children and adolescents and young adults (AYAs) with STS. Methods: We performed a population-based analysis of children and AYAs hospitalized within 1 year of diagnosis with first primary STS (2000-2014) using the California Cancer Registry linked with hospitalization data. Patients were categorized based on receiving all inpatient treatments at a SCC versus part/none. Multivariable Cox proportional hazards regression identified factors associated with overall and STS-specific survival by age group. Results are presented as adjusted hazard ratios (HRs) and 95% confidence intervals (CIs). Results: Of the 1,674 patients with STS, 142 were children (0-14) and 1,532 were AYAs (15-39) and 89.4% and 40.4% received all inpatient treatments at a SCC, respectively. Overall, the 5-year survival was improved for patients who received all inpatient care at a SCC (59.8% vs. those who received part/none, 50.7%). Multivariable regression analysis found that having all treatments at a SCC was associated with better overall survival (HR, 0.79, CI: 0.65-0.95) in AYAs, but not in children. Conclusions: Our findings demonstrate that treatment for STS at a SCC is associated with better survival in AYAs. Eliminating barriers to treatment of AYAs with STS at SCCs could improve survival in this population.
Background: Soft tissue sarcomas (STS) are a heterogeneous group of tumors whose management benefits from a multidisciplinary therapeutic approach. Published data suggest that cancer treatment at a specialized cancer center (SCC) can improve survival in other cancers. Therefore, we examined the impact of the location of treatment on survival in children and adolescents and young adults (AYAs) with STS. Methods: We performed a population-based analysis of children and AYAs hospitalized within 1 year of diagnosis with first primary STS (2000-2014) using the California Cancer Registry linked with hospitalization data. Patients were categorized based on receiving all inpatient treatments at a SCC versus part/none. Multivariable Cox proportional hazards regression identified factors associated with overall and STS-specific survival by age group. Results are presented as adjusted hazard ratios (HRs) and 95% confidence intervals (CIs). Results: Of the 1,674 patients with STS, 142 were children (0-14) and 1,532 were AYAs (15-39) and 89.4% and 40.4% received all inpatient treatments at a SCC, respectively. Overall, the 5-year survival was improved for patients who received all inpatient care at a SCC (59.8% vs. those who received part/none, 50.7%). Multivariable regression analysis found that having all treatments at a SCC was associated with better overall survival (HR, 0.79, CI: 0.65-0.95) in AYAs, but not in children. Conclusions: Our findings demonstrate that treatment for STS at a SCC is associated with better survival in AYAs. Eliminating barriers to treatment of AYAs with STS at SCCs could improve survival in this population.
Authors: Abha A Gupta; James R Anderson; Alberto S Pappo; Sheri L Spunt; Roshni Dasgupta; Daniel J Indelicato; Douglas S Hawkins Journal: Cancer Date: 2011-07-14 Impact factor: 6.860
Authors: Alberto S Pappo; Meenakshi Devidas; Jessee Jenkins; Bhaskar Rao; Robert Marcus; Patrick Thomas; Mark Gebhardt; Charles Pratt; Holcombe E Grier Journal: J Clin Oncol Date: 2005-03-14 Impact factor: 44.544
Authors: Abha A Gupta; Yueh-Yun Chi; James R Anderson; Elizabeth Lyden; Brenda Weigel; Carola Arndt; William H Meyer; Abby Rosenberg; Douglas S Hawkins Journal: Pediatr Blood Cancer Date: 2017-03-23 Impact factor: 3.167
Authors: Andrea Ferrari; Iyad Sultan; Tseng Tien Huang; Carlos Rodriguez-Galindo; Ahmad Shehadeh; Cristina Meazza; Kirsten K Ness; Michela Casanova; Sheri L Spunt Journal: Pediatr Blood Cancer Date: 2011-07-25 Impact factor: 3.167
Authors: C B Pratt; A S Pappo; P Gieser; J J Jenkins; A Salzbergdagger; J Neff; B Rao; D Green; P Thomas; R Marcus; D Parham; H Maurer Journal: J Clin Oncol Date: 1999-04 Impact factor: 44.544
Authors: Hude Quan; Vijaya Sundararajan; Patricia Halfon; Andrew Fong; Bernard Burnand; Jean-Christophe Luthi; L Duncan Saunders; Cynthia A Beck; Thomas E Feasby; William A Ghali Journal: Med Care Date: 2005-11 Impact factor: 2.983
Authors: Alexander L Lazarides; David L Kerr; Daniel P Nussbaum; R Timothy Kreulen; Jason A Somarelli; Dan G Blazer; Brian E Brigman; William C Eward Journal: Clin Orthop Relat Res Date: 2019-04 Impact factor: 4.176
Authors: Carly Westermann; Jennine Weller; Felipe Pedroso; Joe Canner; Christine A Pratilas; Daniel S Rhee Journal: Pediatr Blood Cancer Date: 2020-09-17 Impact factor: 3.167